On August 20, 2024, Fady Malik, Executive Vice President of Research & Development at Cytokinetics Inc (CYTK, Financial), sold 7,300 shares of the company. The transaction was documented in a recent SEC Filing. Following this sale, the insider now owns 125,004 shares of Cytokinetics Inc.
Cytokinetics Inc is a biopharmaceutical company focused on the discovery and development of next-generation therapeutics for diseases characterized by impaired muscle function. The company is committed to advancing innovations in muscle biology directed towards addressing unmet medical needs in severe diseases.
Over the past year, Fady Malik has sold a total of 148,223 shares and has not purchased any shares. This recent transaction is part of a broader trend observed within the company, where there have been 45 insider sells and no insider buys over the past year.
On the date of the sale, shares of Cytokinetics Inc were trading at $56.25, giving the company a market cap of approximately $6.618 billion.
The stock's valuation metrics show a GF Value of $3.28, leading to a price-to-GF-Value ratio of 17.15, indicating that the stock is Significantly Overvalued. The GF Value is calculated based on historical trading multiples, a GuruFocus adjustment factor, and future business performance estimates.
Investors and analysts monitoring Cytokinetics Inc will continue to watch insider transaction trends and valuation metrics closely to gauge the company's financial health and market position.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
